Privately owned biotech company Apaxen SA chose Bart Wuurman as CEO.
Ken Keller, president and CEO of American Regent Inc. – a Daiichi Sankyo Group company – is shifting to a new role as the global head of Oncology Business at Daiichi Sankyo Inc. effective April 1, 2021.
Ipsen named Philippe Lopes-Fernandes executive VP, chief business officer.
Norman Sussman, M.D., was appointed chief medical officer of Durect Corp., a biopharmaceutical company that is focused on the development of treatments for acute organ injury and chronic liver diseases.
CVS Health Corp. named Daniel Finke executive VP, CVS Health and president, Health Care Benefits Segment (HCB) effective February 1, 2021.
Sandra Aung, Ph.D., joined OncoSec Medical Inc. – a company developing late-stage intra-tumoral cancer immunotherapies – as senior VP, chief clinical development officer.
Kathi Rinesmith, R.Ph., M.S., was named senior VP of regulatory affairs at Aprecia, the 3DP Pharmaceutical Company.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, named Barbara Duncan as chairperson of the Fusion Board of Directors.
Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, appointed antibody therapeutics pioneer Dr. James N. Woody as executive chairman.
ProQR Therapeutics named Naveed Shams, M.D., Ph.D., as chief scientific officer.